RS60347B1 - Karbamoiloksimetil triazol cikloheksilne kiseline kao antagonisti lpa - Google Patents
Karbamoiloksimetil triazol cikloheksilne kiseline kao antagonisti lpaInfo
- Publication number
- RS60347B1 RS60347B1 RS20200603A RSP20200603A RS60347B1 RS 60347 B1 RS60347 B1 RS 60347B1 RS 20200603 A RS20200603 A RS 20200603A RS P20200603 A RSP20200603 A RS P20200603A RS 60347 B1 RS60347 B1 RS 60347B1
- Authority
- RS
- Serbia
- Prior art keywords
- methyl
- independently selected
- alkyl
- oxy
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/08—Saturated compounds containing ether groups, groups, groups, or groups
- C07C62/10—Saturated compounds containing ether groups, groups, groups, or groups with a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352792P | 2016-06-21 | 2016-06-21 | |
| EP17734594.9A EP3472148B1 (en) | 2016-06-21 | 2017-06-20 | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists |
| PCT/US2017/038216 WO2017223016A1 (en) | 2016-06-21 | 2017-06-20 | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS60347B1 true RS60347B1 (sr) | 2020-07-31 |
Family
ID=59258388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20200603A RS60347B1 (sr) | 2016-06-21 | 2017-06-20 | Karbamoiloksimetil triazol cikloheksilne kiseline kao antagonisti lpa |
| RS20211353A RS62524B1 (sr) | 2016-06-21 | 2017-06-20 | Antagonisti lpa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20211353A RS62524B1 (sr) | 2016-06-21 | 2017-06-20 | Antagonisti lpa |
Country Status (32)
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| KR102725744B1 (ko) | 2017-12-19 | 2024-11-01 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 피라졸 아진 |
| JP7369125B2 (ja) * | 2017-12-19 | 2023-10-25 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのイソキサゾールｏ－架橋カルバモイルシクロヘキシル酸 |
| JP7212047B2 (ja) * | 2017-12-19 | 2023-01-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール |
| US11319309B2 (en) | 2017-12-19 | 2022-05-03 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as LPA antagonists |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| WO2019126087A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
| CA3085561A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| JP7202383B2 (ja) | 2017-12-19 | 2023-01-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸 |
| CN111712492B (zh) | 2017-12-19 | 2024-05-31 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸三唑唑类 |
| PE20210655A1 (es) | 2017-12-19 | 2021-03-31 | Bristol Myers Squibb Co | Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa |
| ES2962367T3 (es) | 2017-12-19 | 2024-03-18 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA) |
| JP7412424B2 (ja) * | 2018-09-18 | 2024-01-12 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのオキサビシクロ酸 |
| KR102800284B1 (ko) * | 2018-09-18 | 2025-04-23 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헵틸 산 |
| ES2946657T3 (es) * | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| AU2019362770B2 (en) * | 2018-10-15 | 2025-01-23 | Bristol-Myers Squibb Company | Radioligands for imaging the LPA1 receptor |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| CN111434653A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| CN113939502A (zh) | 2019-04-16 | 2022-01-14 | 百时美施贵宝公司 | 用于制备氨基甲酰氧基甲基三唑环己酸化合物的方法 |
| US12466804B2 (en) | 2019-06-18 | 2025-11-11 | Bristol-Myers Squibb Company | Cyclobutyl carboxylic acids as LPA antagonists |
| KR20220024548A (ko) | 2019-06-18 | 2022-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 트리아졸 카르복실산 |
| EP3986552B1 (en) * | 2019-06-18 | 2024-09-18 | Bristol-Myers Squibb Company | Isoxazole carboxylic acids as lpa antagonists |
| IL289951B2 (en) | 2019-07-30 | 2025-10-01 | Taisho Pharmaceutical Co Ltd | Urea compound as an LPA1 receptor antagonist |
| CN114728168B (zh) * | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| US20230014137A1 (en) * | 2019-11-29 | 2023-01-19 | Ono Pharmaceutical Co., Ltd. | Compound having lysophosphatidic acid receptor agonist activity and pharmaceutical use thereof |
| US20230061417A1 (en) | 2019-12-12 | 2023-03-02 | Chiesi Farmaceutici S.P.A. | Thienopyrimidine derivatives as lpa receptor 2 inhibitors |
| JP2023505703A (ja) | 2019-12-12 | 2023-02-10 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害剤としての芳香族アミド誘導体 |
| US12404270B2 (en) | 2019-12-12 | 2025-09-02 | Chiesi Farmaceutici S.P.A. | Quinazoline derivatives as LPA receptor 2 inhibitors |
| CN111195254B (zh) * | 2020-02-25 | 2021-03-16 | 中国医学科学院阜外医院 | Lpa2及其激动剂的应用 |
| KR102393079B1 (ko) | 2020-02-28 | 2022-04-29 | 한국화학연구원 | 가축 호흡기 질환의 예방 또는 치료용 조성물 |
| US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| TWI843503B (zh) * | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| ES2991765T3 (es) | 2020-07-16 | 2024-12-04 | Chiesi Farm Spa | Derivados del ácido amido ciclohexano como inhibidores del receptor de LPA |
| WO2022083703A1 (en) * | 2020-10-22 | 2022-04-28 | Lhotse Bio, Inc. | Compounds and compositions for treating conditions associated with lpa receptor activity |
| WO2022100623A1 (zh) * | 2020-11-10 | 2022-05-19 | 武汉人福创新药物研发中心有限公司 | 氮取代杂环噻吩类化合物及其用途 |
| CN114456147B (zh) * | 2020-11-10 | 2025-07-15 | 武汉人福创新药物研发中心有限公司 | 氧取代氨基碳酸酯噻吩类化合物 |
| WO2022100625A1 (zh) * | 2020-11-10 | 2022-05-19 | 武汉人福创新药物研发中心有限公司 | 氮取代氨基碳酸酯噻吩类化合物及其用途 |
| CN114621135B (zh) * | 2020-12-11 | 2024-01-30 | 上海拓界生物医药科技有限公司 | 一种lpa1小分子拮抗剂 |
| CN112778187B (zh) * | 2021-01-06 | 2022-10-28 | 烟台舜康生物科技有限公司 | 一种海那替尼中间体的合成方法及所得的海纳替尼中间体 |
| WO2022174882A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022174883A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| US20240190860A1 (en) | 2021-03-24 | 2024-06-13 | Chiesi Farmaceutici S.P.A. | 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors |
| AU2022273631B2 (en) | 2021-05-11 | 2025-04-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| EP4360650A4 (en) * | 2021-06-25 | 2025-01-15 | Japanese Foundation For Cancer Research | NEW THERAPEUTIC AGENT FOR SUPPRESSING METASTASES AND PROLIFERATION OF OSTEOSARCOMA AND GLIOM |
| KR20240038004A (ko) * | 2021-07-20 | 2024-03-22 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | Lpa1 소분자 길항제 |
| JP2024540937A (ja) * | 2021-10-21 | 2024-11-06 | ローツェ・バイオ・インコーポレイテッド | Ｌｐａ受容体活性に関連する状態を処置するための化合物および組成物 |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| WO2023109878A1 (zh) * | 2021-12-15 | 2023-06-22 | 武汉人福创新药物研发中心有限公司 | 三氮唑类lpar1拮抗剂及其用途 |
| US20250066341A1 (en) | 2021-12-23 | 2025-02-27 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
| WO2023170025A1 (en) | 2022-03-08 | 2023-09-14 | Chiesi Farmaceutici S.P.A. | Amido cyclopropyl derivatives as lpa receptor inhibitors |
| JP2025509588A (ja) | 2022-03-15 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | （１ｓ，３ｓ）－３－ヒドロキシシクロヘキサン－１－カルボン酸化合物の生体触媒合成 |
| AU2023411001A1 (en) | 2022-12-23 | 2025-08-07 | Bristol-Myers Squibb Company | Crystalline forms of a lpa1 antagonist |
| JP2026501005A (ja) | 2022-12-23 | 2026-01-13 | ブリストル－マイヤーズ スクイブ カンパニー | 間質性肺疾患を治療するためのｌｐａ１拮抗薬 |
| EP4637765A1 (en) | 2022-12-23 | 2025-10-29 | Bristol-Myers Squibb Company | Lpa1 antagonists for treating interstitial lung disease |
| TW202440089A (zh) | 2022-12-23 | 2024-10-16 | 美商必治妥美雅史谷比公司 | 用於治療間質性肺病之lpa1拮抗劑 |
| US20260226025A1 (en) * | 2023-01-19 | 2026-08-06 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt and crystal form of triazole compound, and preparation method therefor |
| IL326963A (en) | 2023-09-08 | 2026-05-01 | Haisco Pharmaceutical Group Co Ltd | LPAR1 antagonist and its use |
| CN121773091A (zh) * | 2023-09-08 | 2026-03-31 | 西藏海思科制药有限公司 | 杂芳环衍生物的lpar1拮抗剂及其用途 |
| CN117024409A (zh) * | 2023-10-10 | 2023-11-10 | 药康众拓(北京)医药科技有限公司 | 氘代lpa1抑制剂化合物及其用途 |
| CN117919254A (zh) * | 2024-01-12 | 2024-04-26 | 中国医学科学院药用植物研究所 | 一种三唑类化合物在制备防治缺血性脑卒中药物中的应用 |
| WO2025162421A1 (zh) * | 2024-02-04 | 2025-08-07 | 西藏海思科制药有限公司 | Lpar1拮抗剂及其用途 |
| WO2025259831A1 (en) * | 2024-06-13 | 2025-12-18 | Bristol-Myers Squibb Company | Crystal forms of a lpa1 antagonist |
| WO2026061483A1 (zh) * | 2024-09-19 | 2026-03-26 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
| WO2026119206A1 (zh) * | 2024-12-05 | 2026-06-11 | 海思科医药集团股份有限公司 | Lpar1拮抗剂药物组合物及其在医药上的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1695422A (en) | 1928-12-18 | A cobpobation | ||
| US1695432A (en) | 1924-03-18 | 1928-12-18 | Arthur W Lovejoy | Toilet-paper holder |
| US1695455A (en) | 1925-12-07 | 1928-12-18 | Delpech Jacques | Apparatus for the manufacture of artificial filaments |
| US1677284A (en) | 1926-04-23 | 1928-07-17 | Goodrich Co B F | Sheet material and method of making and mounting the same |
| US1695431A (en) | 1926-10-05 | 1928-12-18 | Fred H Linley | Combustion control in steam-boiler furnaces |
| GB267434A (en) | 1926-11-12 | 1927-03-17 | Thomas Whyte Guthrie | An improved billiard-cue tip |
| US1695454A (en) | 1927-05-23 | 1928-12-18 | Edward J Coyne | Door spring |
| IT1237793B (it) * | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
| EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| AU2005214375A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| DE102004038403B4 (de) | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| GB0806794D0 (en) | 2008-04-15 | 2008-05-14 | Ludwig Inst Cancer Res | Therapeutic compounds |
| GB2474120B (en) * | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| RU2582337C2 (ru) | 2010-11-09 | 2016-04-27 | Ф.Хоффманн-Ля Рош Аг | Производные триазола в качестве лигандов рецепторов гамк |
| WO2012078593A2 (en) | 2010-12-07 | 2012-06-14 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and uses thereof |
| US8785442B2 (en) * | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| US9527807B2 (en) | 2011-04-05 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| US20140329871A1 (en) * | 2011-12-04 | 2014-11-06 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| SG11201407220YA (en) * | 2012-06-20 | 2014-12-30 | Hoffmann La Roche | N-alkyltriazole compounds as lpar antagonists |
| HK1206339A1 (en) | 2012-06-20 | 2016-01-08 | 霍夫曼-拉罗奇有限公司 | N-aryltriazole compounds as lpar antagonists |
| WO2014001279A1 (en) * | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| AR108745A1 (es) | 2016-06-21 | 2018-09-19 | Syngenta Participations Ag | Derivados de oxadiazol microbiocidas |
| KR102725744B1 (ko) | 2017-12-19 | 2024-11-01 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 피라졸 아진 |
| PE20210655A1 (es) | 2017-12-19 | 2021-03-31 | Bristol Myers Squibb Co | Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa |
| US11319309B2 (en) | 2017-12-19 | 2022-05-03 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as LPA antagonists |
| JP7369125B2 (ja) | 2017-12-19 | 2023-10-25 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのイソキサゾールｏ－架橋カルバモイルシクロヘキシル酸 |
| ES2962367T3 (es) | 2017-12-19 | 2024-03-18 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA) |
| CA3085561A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| JP7202383B2 (ja) | 2017-12-19 | 2023-01-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸 |
| JP7212047B2 (ja) | 2017-12-19 | 2023-01-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| WO2019126087A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
-
2017
- 2017-06-19 AR ARP170101698A patent/AR108838A1/es active IP Right Grant
- 2017-06-20 ES ES17734594T patent/ES2785951T3/es active Active
- 2017-06-20 WO PCT/US2017/038216 patent/WO2017223016A1/en not_active Ceased
- 2017-06-20 SM SM20210614T patent/SMT202100614T1/it unknown
- 2017-06-20 TW TW106120551A patent/TWI725200B/zh active
- 2017-06-20 HR HRP20200586TT patent/HRP20200586T1/hr unknown
- 2017-06-20 EP EP17734594.9A patent/EP3472148B1/en active Active
- 2017-06-20 KR KR1020197001470A patent/KR102377340B1/ko active Active
- 2017-06-20 PL PL17734594T patent/PL3472148T3/pl unknown
- 2017-06-20 PT PT177345949T patent/PT3472148T/pt unknown
- 2017-06-20 RS RS20200603A patent/RS60347B1/sr unknown
- 2017-06-20 PE PE2018003307A patent/PE20190211A1/es unknown
- 2017-06-20 AU AU2017281439A patent/AU2017281439B2/en active Active
- 2017-06-20 MY MYPI2018002672A patent/MY195782A/en unknown
- 2017-06-20 SI SI201730979T patent/SI3666771T1/sl unknown
- 2017-06-20 JP JP2018566914A patent/JP7073281B2/ja active Active
- 2017-06-20 DK DK17734594.9T patent/DK3472148T3/da active
- 2017-06-20 DK DK20154651.2T patent/DK3666771T3/da active
- 2017-06-20 CN CN202210167783.7A patent/CN114601830A/zh active Pending
- 2017-06-20 SG SG11201811321TA patent/SG11201811321TA/en unknown
- 2017-06-20 ME MEP-2020-141A patent/ME03804B/me unknown
- 2017-06-20 LT LTEP20154651.2T patent/LT3666771T/lt unknown
- 2017-06-20 ES ES20154651T patent/ES2895385T3/es active Active
- 2017-06-20 UY UY0001037302A patent/UY37302A/es active IP Right Grant
- 2017-06-20 SM SM20200274T patent/SMT202000274T1/it unknown
- 2017-06-20 HU HUE20154651A patent/HUE057211T2/hu unknown
- 2017-06-20 US US15/628,104 patent/US10071078B2/en not_active Ceased
- 2017-06-20 EP EP20154651.2A patent/EP3666771B1/en active Active
- 2017-06-20 PT PT201546512T patent/PT3666771T/pt unknown
- 2017-06-20 EA EA201892710A patent/EA037585B1/ru not_active IP Right Cessation
- 2017-06-20 SI SI201730240T patent/SI3472148T1/sl unknown
- 2017-06-20 HU HUE17734594A patent/HUE049944T2/hu unknown
- 2017-06-20 HR HRP20211708TT patent/HRP20211708T8/hr unknown
- 2017-06-20 RS RS20211353A patent/RS62524B1/sr unknown
- 2017-06-20 LT LTEP17734594.9T patent/LT3472148T/lt unknown
- 2017-06-20 TW TW110110259A patent/TWI757128B/zh active
- 2017-06-20 MX MX2018015563A patent/MX381205B/es unknown
- 2017-06-20 PL PL20154651T patent/PL3666771T3/pl unknown
- 2017-06-20 CA CA3029202A patent/CA3029202C/en active Active
- 2017-06-20 KR KR1020227008719A patent/KR102463621B1/ko active Active
- 2017-06-20 CN CN201780050555.9A patent/CN109963843B/zh active Active
-
2018
- 2018-07-18 US US16/038,739 patent/US10576062B2/en active Active
- 2018-12-17 IL IL263767A patent/IL263767B/en unknown
- 2018-12-19 ZA ZA2018/08580A patent/ZA201808580B/en unknown
- 2018-12-20 CL CL2018003708A patent/CL2018003708A1/es unknown
-
2019
- 2019-01-17 CO CONC2019/0000471A patent/CO2019000471A2/es unknown
-
2020
- 2020-01-02 US US16/732,387 patent/US11007180B2/en active Active
- 2020-06-10 CY CY20201100531T patent/CY1123443T1/el unknown
- 2020-09-03 US US17/011,592 patent/USRE49352E1/en active Active
-
2021
- 2021-04-05 US US17/221,859 patent/US20210244711A1/en not_active Abandoned
- 2021-07-30 AU AU2021209334A patent/AU2021209334B2/en active Active
- 2021-11-19 CY CY20211101007T patent/CY1124737T1/el unknown
-
2022
- 2022-04-12 US US17/718,760 patent/US20220249443A1/en not_active Abandoned
- 2022-05-11 JP JP2022078334A patent/JP7312295B2/ja active Active
-
2023
- 2023-08-22 US US18/453,431 patent/US20230390249A1/en not_active Abandoned
-
2024
- 2024-09-03 US US18/822,597 patent/US20250057815A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7312295B2 (ja) | Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸 | |
| EP3728196B1 (en) | Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists | |
| RS62710B1 (sr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| WO2020257135A1 (en) | Triazole carboxylic acids as lpa antagonists | |
| HK40030550A (en) | Lpa antagonists | |
| HK40030550B (en) | Lpa antagonists | |
| HK40006813A (en) | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists | |
| HK40006813B (en) | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists | |
| BR112018076558B1 (pt) | Ácidos cicloexil carbamoiloximetil triazol como antagonistas de lpa, composição farmacêutica e seus usos | |
| BR112020011776B1 (pt) | Ácidos de carbamoil ciclo-hexila n-ligados a triazol como antagonistas de lpa, composição e usos | |
| EA042829B1 (ru) | Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa | |
| NZ750013B2 (en) | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists |